JP2016522179A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522179A5 JP2016522179A5 JP2016509298A JP2016509298A JP2016522179A5 JP 2016522179 A5 JP2016522179 A5 JP 2016522179A5 JP 2016509298 A JP2016509298 A JP 2016509298A JP 2016509298 A JP2016509298 A JP 2016509298A JP 2016522179 A5 JP2016522179 A5 JP 2016522179A5
- Authority
- JP
- Japan
- Prior art keywords
- general formula
- tamoxifen
- derivative
- formula
- isomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2013-308A CZ2013308A3 (cs) | 2013-04-24 | 2013-04-24 | Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2 |
| CZPV2013-308 | 2013-04-24 | ||
| CZ2014-66A CZ305571B6 (cs) | 2014-01-29 | 2014-01-29 | Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2 |
| CZPV2014-66 | 2014-01-29 | ||
| PCT/CZ2014/000035 WO2014173374A1 (en) | 2013-04-24 | 2014-04-07 | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016522179A JP2016522179A (ja) | 2016-07-28 |
| JP2016522179A5 true JP2016522179A5 (enExample) | 2017-04-06 |
| JP6375091B2 JP6375091B2 (ja) | 2018-08-15 |
Family
ID=50677895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509298A Expired - Fee Related JP6375091B2 (ja) | 2013-04-24 | 2014-04-07 | 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9896466B2 (enExample) |
| EP (1) | EP2989110B1 (enExample) |
| JP (1) | JP6375091B2 (enExample) |
| KR (1) | KR101764991B1 (enExample) |
| CN (1) | CN105452265B (enExample) |
| AU (1) | AU2014256546B2 (enExample) |
| CA (1) | CA2909994C (enExample) |
| CY (1) | CY1120821T1 (enExample) |
| DK (1) | DK2989110T3 (enExample) |
| EA (1) | EA029881B1 (enExample) |
| ES (1) | ES2699099T3 (enExample) |
| GE (2) | GEAP201813996A (enExample) |
| HR (1) | HRP20181872T1 (enExample) |
| HU (1) | HUE042239T2 (enExample) |
| MD (1) | MD4626C1 (enExample) |
| NZ (1) | NZ713589A (enExample) |
| PL (1) | PL2989110T3 (enExample) |
| PT (1) | PT2989110T (enExample) |
| SI (1) | SI2989110T1 (enExample) |
| UA (1) | UA116469C2 (enExample) |
| WO (1) | WO2014173374A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA123628C2 (uk) * | 2015-07-03 | 2021-05-05 | Баєр Кропсаєнс Акціенгезельшафт | Гербіцидно активні похідні n-(1,3,4-оксадіазол-2-іл)арилкарбоксаміду |
| EP3317268B1 (de) * | 2015-07-03 | 2019-08-28 | Bayer CropScience Aktiengesellschaft | Herbizid wirksame n-(tetrazol-5-yl)- und n-(triazol-5-yl)arylcarboxamid-derivate |
| MA43141A (fr) * | 2016-07-12 | 2018-09-05 | Accutar Biotechnology Inc | Nouveaux composés et leurs utilisations |
| US11040019B2 (en) | 2016-08-19 | 2021-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration |
| EP3330274A1 (en) * | 2016-12-01 | 2018-06-06 | Springtide Ventures s.r.o. | Compounds for treatment of senescence-related disorders |
| WO2018195434A1 (en) | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| WO2018195446A1 (en) | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
| US11160821B2 (en) | 2017-05-19 | 2021-11-02 | Lunella Biotech, Inc. | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| RU2020116649A (ru) | 2017-10-24 | 2021-11-30 | Лунелла Байотек, Инк. | Митофлавосцины: нацеливание на флавин-содержащие ферменты устраняет злокачественные стволовые клетки (cscs) посредством ингибирования митохондриального дыхания |
| WO2019104115A1 (en) | 2017-11-24 | 2019-05-31 | Lunella Biotech, Inc. | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells |
| CA3083487A1 (en) | 2017-12-01 | 2019-06-06 | Lunella Biotech, Inc. | Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| US11541120B2 (en) | 2017-12-05 | 2023-01-03 | Anthos Partners, Lp | Phosphonium-based ionic drug conjugates |
| US11559527B2 (en) | 2017-12-20 | 2023-01-24 | Lunella Biotech, Inc. | Targeting mitochondrial fission through mDIVI-1 derivatives |
| WO2020214754A1 (en) * | 2019-04-16 | 2020-10-22 | Lunella Biotech, Inc. | Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments |
| EP3753944A1 (en) | 2019-06-17 | 2020-12-23 | Institute Of Biotechnology Cas, V.V.I. | 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0551434B1 (en) * | 1990-10-01 | 1995-11-15 | The Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives and uses thereof |
| JP3635708B2 (ja) * | 1995-03-06 | 2005-04-06 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子 |
| TWI309571B (en) * | 2002-12-31 | 2009-05-11 | Ind Tech Res Inst | Delivery carrier for targeting cells haring over-expressed estrogen |
| CN1839142B (zh) * | 2003-08-22 | 2010-06-16 | 澳新制药公司 | 用作靶向线粒体的抗氧化剂的线粒体醌衍生物 |
| WO2006005759A2 (en) * | 2004-07-13 | 2006-01-19 | Oridis Biomed Forschungs- Und Entwicklungs Gmbh | Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers |
| WO2009111846A1 (en) * | 2008-03-14 | 2009-09-17 | Stephen John Ralph | Mitochondrially delivered anti-cancer compounds |
| AP2011005974A0 (en) * | 2009-04-17 | 2011-12-31 | Colby Pharmaceutical Company | Pharmaceutically active compositions comprising oxidative stress modulators OSM, new chemical entities, compositions and uses. |
| WO2011129837A1 (en) * | 2010-04-16 | 2011-10-20 | Olema Pharmaceuticals, Inc. | Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer |
-
2014
- 2014-04-07 WO PCT/CZ2014/000035 patent/WO2014173374A1/en not_active Ceased
- 2014-04-07 HU HUE14721738A patent/HUE042239T2/hu unknown
- 2014-04-07 ES ES14721738T patent/ES2699099T3/es active Active
- 2014-04-07 MD MD20150117A patent/MD4626C1/ro not_active IP Right Cessation
- 2014-04-07 PT PT14721738T patent/PT2989110T/pt unknown
- 2014-04-07 KR KR1020157030376A patent/KR101764991B1/ko not_active Expired - Fee Related
- 2014-04-07 EP EP14721738.4A patent/EP2989110B1/en active Active
- 2014-04-07 DK DK14721738.4T patent/DK2989110T3/en active
- 2014-04-07 NZ NZ713589A patent/NZ713589A/en not_active IP Right Cessation
- 2014-04-07 EA EA201591918A patent/EA029881B1/ru unknown
- 2014-04-07 GE GEAP201813996A patent/GEAP201813996A/en unknown
- 2014-04-07 JP JP2016509298A patent/JP6375091B2/ja not_active Expired - Fee Related
- 2014-04-07 CN CN201480033316.9A patent/CN105452265B/zh not_active Expired - Fee Related
- 2014-04-07 SI SI201430928T patent/SI2989110T1/sl unknown
- 2014-04-07 UA UAA201510642A patent/UA116469C2/uk unknown
- 2014-04-07 HR HRP20181872TT patent/HRP20181872T1/hr unknown
- 2014-04-07 US US14/786,710 patent/US9896466B2/en not_active Expired - Fee Related
- 2014-04-07 CA CA2909994A patent/CA2909994C/en active Active
- 2014-04-07 AU AU2014256546A patent/AU2014256546B2/en not_active Ceased
- 2014-04-07 PL PL14721738T patent/PL2989110T3/pl unknown
-
2015
- 2015-04-07 GE GEAP201513996A patent/GEP20186868B/en unknown
-
2018
- 2018-11-06 CY CY181101155T patent/CY1120821T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6375091B2 (ja) | 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体 | |
| JP2017518302A5 (enExample) | ||
| Tang et al. | Synthesis and biological evaluation of 2, 3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERα and VEGFR-2 | |
| KR20140008297A (ko) | 도파민성 안정제로서 유용한 프리도피딘의 듀테륨화된 유사체 | |
| TW202545942A (zh) | Ｃｄｋ抑制劑 | |
| AU2022205484B2 (en) | Pyridone multiple-membered ring derivatives and use thereof | |
| JP2019519593A5 (enExample) | ||
| JP2017506640A5 (enExample) | ||
| NO20054526L (no) | Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen | |
| EP3416950A1 (en) | Max binders as myc modulators and uses thereof | |
| JP2014530181A5 (enExample) | ||
| Zbieg et al. | Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer | |
| JP2013523867A5 (enExample) | ||
| Mahindra et al. | Unravelling Potential Mechanisms of Piper retrofractum Vahl. Bioactive Compounds as Cervical Cancer Chemopreventive Agent by Bioinformatic Approach | |
| CA2878987C (en) | Use of vegfr-3 inhibitors for treating hepatocellular carcinoma | |
| JP2010509306A5 (enExample) | ||
| JP2019517474A5 (enExample) | ||
| JP2015534958A (ja) | Ｎ−置換３，４−ビス（カテコール）ピロール化合物、その調製、及びガンの治療のためのその使用 | |
| JP2020506886A5 (enExample) | ||
| Yu et al. | Discovery of potent and orally available small molecule inhibitors of the SOS1-KRAS interaction | |
| Corcoran | Studies toward the synthesis of radioactive tyrosine kinase inhibitors, steroidal antiestrogens, and indoles as probes of biological systems | |
| HK1216317B (en) | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level | |
| Kluckova et al. | 424 Role of the Ubiquinone Site of Complex II in Apoptosis Induction and Malignant Transformation | |
| Fernandez-Nogueira et al. | 423 Acquisition of Resistance to Anti-Her2 Therapies Promotes a Different Microenvironment Crosstalk Capability | |
| HK1243598B (en) | Combination therapies |